Imaging expression of prostate‐specific membrane antigen and response to PSMA‐targeted β‐emitting radionuclide therapies in metastatic castration‐resistant prostate cancer
Abstract
Prostate‐specific membrane antigen (PSMA)‐targeted radionuclide therapy (TRT) has demonstrated efficacy and tolerability with a dose–response effect in phase I/II trials in men with metastatic castration‐resistant prostate cancer (mCRPC). The need for positive PSMA imaging before PSMA‐TRT to select patients is largely practiced, but its utility is not proven. Given target heterogeneity, developing a biomarker to identify the optimal patient population remains an unmet need. The aim of this study was to assess PSMA uptake by imaging and response to PSMA‐TRT.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 19, 2021
- Source ID
- 10.1002/pros.24104
Entities
People
- Ana M. Molina
- Charlene Thomas
- David M. Nanus
- Joseph R. Osborne
- Muhammad Junaid Niaz
- Myrto Skafida
- Neil Harrison Bander
- Panagiotis J Vlachostergios
- Paul J. Christos
- Scott T Tagawa
- Seyed Ali Mosallaie
Organizations
- United States Department of Defense
- Weill Cornell Medicine